{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:04:29Z","timestamp":1790575469711,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Our aim was to evaluate the prognostic value of initial total metabolic tumour volume (TMTV) in a population of patients with advanced-stage Hodgkin\u2019s lymphoma (HL). We retrospectively included 179 patients with stage IIb-III-IV Hodgkin\u2019s disease who received BEACOPP or ABVD as the first-line treatment. The initial TMTV was determined using a semi-automatic method for each patient. We analysed its prognostic value in terms of 5-year progression-free survival (PFS), overall survival, and positron emission tomography (PET) response after two courses of chemotherapy. Considering all the treatments and using a threshold of 217 cm\n                    <jats:sup>3<\/jats:sup>\n                    , TMTV was predictive of 5-year PFS and PET response after two courses of chemotherapy. In multivariable analysis involving TMTV, IPI score, and the first treatment received, TMTV remained a baseline prognostic factor for 5-year PFS. In the subgroup of patients treated with BEACOPP with a threshold of 331 cm\n                    <jats:sup>3<\/jats:sup>\n                    , TMTV was predictive of PET response, but not 5-year PFS (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.087). The combined analysis of TMTV and PET response enabled the individualisation of a subgroup of patients (low TMTV and complete response on PET) with a very low risk of recurrence. Baseline TMTV appears to be a useful independent prognostic factor for predicting relapse in advanced-stage HL in ABVD subgroup, with a tendency of survival curves separation in BEACOPP subgroup.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-02734-w","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T06:04:42Z","timestamp":1638338682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin\u2019s lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Pierre","family":"Pinochet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Texte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoullas-Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorina-Dana","family":"Mihailescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8621-9622","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"2734_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell, S. M. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 93, 704\u2013715. https:\/\/doi.org\/10.1002\/ajh.25071 (2018).","journal-title":"Am. J. Hematol."},{"key":"2734_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood.V73.1.47.47","volume":"73","author":"M Tubiana","year":"1989","unstructured":"Tubiana, M. et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin\u2019s disease. The EORTC Lymphoma Group controlled clinical trials: 1964\u20131987. Blood 73, 47\u201356 (1989).","journal-title":"Blood"},{"key":"2734_CR3","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever, D. & Diehl, V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N. Engl. J. Med. 339, 1506\u20131514. https:\/\/doi.org\/10.1056\/NEJM199811193392104 (1998).","journal-title":"N. Engl. J. Med."},{"key":"2734_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"R-O Casasnovas","year":"2019","unstructured":"Casasnovas, R.-O. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 20, 202\u2013215. https:\/\/doi.org\/10.1016\/S1470-2045(18)30784-8 (2019).","journal-title":"Lancet Oncol."},{"key":"2734_CR5","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9, M. P. E. et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial. J. Clin. Oncol. 35, 1786\u20131794. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2734_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","volume":"131","author":"A-S Cottereau","year":"2018","unstructured":"Cottereau, A.-S. et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131, 1456\u20131463. https:\/\/doi.org\/10.1182\/blood-2017-07-795476 (2018).","journal-title":"Blood"},{"key":"2734_CR7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210047","author":"J Mettler","year":"2018","unstructured":"Mettler, J. et al. Metabolic tumour volume for response prediction in advanced-stage hodgkin lymphoma. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.118.210047 (2018).","journal-title":"J. Nucl. Med."},{"key":"2734_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun, S. et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in hodgkin lymphoma. PLoS ONE 10, e0140830. https:\/\/doi.org\/10.1371\/journal.pone.0140830 (2015).","journal-title":"PLoS ONE"},{"key":"2734_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington, S. F. & Meignan, M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J. Nucl. Med. 60, 1096\u20131102. https:\/\/doi.org\/10.2967\/jnumed.119.227249 (2019).","journal-title":"J. Nucl. Med."},{"key":"2734_CR10","unstructured":"R: The R Project for Statistical Computing. Available at: https:\/\/www.r-project.org\/ [Accessed June 30, 2021]."},{"key":"2734_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout, P. E. & Fleiss, J. L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 86, 420\u2013428. https:\/\/doi.org\/10.1037\/\/0033-2909.86.2.420 (1979).","journal-title":"Psychol. Bull."},{"key":"2734_CR12","unstructured":"Davison AC. Bootstrap Methods and their Application.47."},{"key":"2734_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/bjc.1995.364","volume":"72","author":"DG Altman","year":"1995","unstructured":"Altman, D. G., De Stavola, B. L., Love, S. B. & Stepniewska, K. A. Review of survival analyses published in cancer journals. Br. J. Cancer 72, 511\u2013518. https:\/\/doi.org\/10.1038\/bjc.1995.364 (1995).","journal-title":"Br. J. Cancer"},{"key":"2734_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2307\/2336325","volume":"75","author":"Y Hochberg","year":"1988","unstructured":"Hochberg, Y. A Sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800\u2013802. https:\/\/doi.org\/10.2307\/2336325 (1988).","journal-title":"Biometrika"},{"key":"2734_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo, T. K. & Li, M. Y. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J. Chiropr. Med. 15, 155\u2013163. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012 (2016).","journal-title":"J. Chiropr. Med."},{"key":"2734_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","volume":"91","author":"M-K Song","year":"2012","unstructured":"Song, M.-K. et al. Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann. Hematol. 91, 697\u2013703. https:\/\/doi.org\/10.1007\/s00277-011-1357-2 (2012).","journal-title":"Ann. Hematol."},{"key":"2734_CR17","doi-asserted-by":"publisher","first-page":"99587","DOI":"10.18632\/oncotarget.20447","volume":"8","author":"C-C Chang","year":"2017","unstructured":"Chang, C.-C. et al. Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography\/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget 8, 99587\u201399600. https:\/\/doi.org\/10.18632\/oncotarget.20447 (2017).","journal-title":"Oncotarget"},{"key":"2734_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","volume":"45","author":"MN Toledano","year":"2018","unstructured":"Toledano, M. N. et al. Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur. J. Nucl. Med. Mol. Imaging 45, 680\u2013688. https:\/\/doi.org\/10.1007\/s00259-017-3907-x (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2734_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau, A. S. et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann. Oncol. 27, 719\u2013724. https:\/\/doi.org\/10.1093\/annonc\/mdw011 (2016).","journal-title":"Ann. Oncol."},{"key":"2734_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","volume":"41","author":"S Kanoun","year":"2014","unstructured":"Kanoun, S. et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur. J. Nucl. Med. Mol. Imaging 41, 1735\u20131743. https:\/\/doi.org\/10.1007\/s00259-014-2783-x (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2734_CR21","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2016.34.15_suppl.7509","volume":"34","author":"R-O Casasnovas","year":"2016","unstructured":"Casasnovas, R.-O. et al. Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. JCO 34, 7509\u20137509. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.7509 (2016).","journal-title":"JCO"},{"key":"2734_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard, R. et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging 37, 181\u2013200. https:\/\/doi.org\/10.1007\/s00259-009-1297-4 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2734_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan, M. et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur. J. Nucl. Med. Mol. Imaging 41, 1113\u20131122. https:\/\/doi.org\/10.1007\/s00259-014-2705-y (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2734_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020072","author":"F Eude","year":"2021","unstructured":"Eude, F. et al. Reproducibility of baseline tumour metabolic volume measurements in diffuse large B-Cell LymphomA: Is there a superior method?. Metabolites https:\/\/doi.org\/10.3390\/metabo11020072 (2021).","journal-title":"Metabolites"},{"key":"2734_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.628179","volume":"8","author":"P Pinochet","year":"2021","unstructured":"Pinochet, P. et al. Evaluation of an automatic classification algorithm using convolutional neural networks in oncological positron emission tomography. Front. Med. (Lausanne) 8, 628179. https:\/\/doi.org\/10.3389\/fmed.2021.628179 (2021).","journal-title":"Front. Med. (Lausanne)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02734-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:59:05Z","timestamp":1670072345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02734-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2734"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02734-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23195"}}